Clinical trials
Terminated Phase 3 Lung Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 45 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alliance for Clinical Trials in Oncology | 4 |
| CTI BioPharma | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Point Therapeutics | 2 |
| Amgen | 1 |
| Amsterdam UMC, location VUmc | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Centre Francois Baclesse | 1 |
| Checkpoint Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 45 |
| Carcinoma, Non-Small-Cell Lung | 28 |
| Adenocarcinoma of Lung | 4 |
| Neoplasms | 4 |
| Adenocarcinoma, Bronchiolo-Alveolar | 3 |
| Breast Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Neoplasms by Site | 3 |
| Respiratory Tract Neoplasms | 3 |
| Thoracic Neoplasms | 3 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.